$DAAQ

Digital Asset Acquisition Corp.

Insider trades
0
0
1

No SEC Form 4 filings for $DAAQ in the last 30 days.

See all $DAAQ insider activity →
High

Digital Asset Acquisition Corp. (DAAQ): Entry into a Material Definitive Agreement

Digital Asset Acquisition Corp. (DAAQ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0002052162 00-0000000 0002052162 2026-08-13 2026-08-13 0002052162 DAAQ:UnitsEachConsistingOfOneClassOrdinaryShare0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember 2026-08-13 2026-08-13 0002052162 DAAQ:ClassOrdinarySharesParValue0.0001PerShareMember 2026-08-13 2026-08-13

Digital Asset Acquisition Corp. (DAAQU): Entry into a Material Definitive Agreement

Digital Asset Acquisition Corp. (DAAQU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 CONFIDENTIAL Digital Asset Acquisition Corp. FORM OF NON-REDEMPTION AGREEMENT This NON-REDEMPTION AGREEMENT (this “ Agreement ”), dated as of [●], 2026, is made by and among Digital Asset Acquisition Corp. , a Cayman Islands exempted comp

DAAQ sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning DAAQ (Digital Asset Acquisition Corp.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent DAAQ coverage spans financial news, corporate actions and market movers.

What's driving DAAQ

  • Termination removes the announced deal catalyst and increases uncertainty around DAAQ’s next corporate path.

    SEC EDGAR 8-K · Aug 13, 2026

  • Digital Asset Acquisition Corp. (DAAQU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 CONFIDENTIAL Digital Asset Acquisition Corp. FORM OF NON-REDEMPTION AGREEMENT This NON-REDEMPTION AGREEMENT (this “ Agreement ”), dated as of [●], 2026, is made by and among Digital Asset Acquisition Corp. , a Cayman Islands exempted comp

    SEC EDGAR 8-K · Jun 18, 2026

  • Digital Asset Acquisition Corp. (NASDAQ:DAAQW) saw short interest fall 77.4% in May, to 76 shares as of May 15 from 337 shares on April 30, according to the article. With average volume of 2,796 shares, days-to-cover is about 0.0. The stock last traded down $0.05 at $0.45.

    dailypolitical.com · May 29, 2026

  • Minimal direct impact on DAAQ; relevance is limited due to lack of connection to Propanc's activities.

    Benzinga · Nov 10, 2025

  • The private placement indicates strategic growth for Propanc Biopharma, potentially supporting R&D and digital asset initiatives. Limited direct impact expected on DAAQ stock price.

    GlobeNewswire · Nov 10, 2025

alphai scores every news story that mentions DAAQ with an AI model for sentiment and relevance, and aggregates insider trades from Digital Asset Acquisition Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DAAQ

Score
$DAAQHigh

Digital Asset Acquisition Corp. (DAAQ): Entry into a Material Definitive Agreement

Digital Asset Acquisition Corp. (DAAQ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0002052162 00-0000000 0002052162 2026-08-13 2026-08-13 0002052162 DAAQ:UnitsEachConsistingOfOneClassOrdinaryShare0.0001ParValueAndOnehalfOfOneRedeemableWarrantMember 2026-08-13 2026-08-13 0002052162 DAAQ:ClassOrdinarySharesParValue0.0001PerShareMember 2026-08-13 2026-08-13

Digital Asset Acquisition Corp. (DAAQU): Entry into a Material Definitive Agreement

Digital Asset Acquisition Corp. (DAAQU) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 CONFIDENTIAL Digital Asset Acquisition Corp. FORM OF NON-REDEMPTION AGREEMENT This NON-REDEMPTION AGREEMENT (this “ Agreement ”), dated as of [●], 2026, is made by and among Digital Asset Acquisition Corp. , a Cayman Islands exempted comp

$DAAQMed

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline - Propanc Biopharma (NASDAQ:PPCB)

MELBOURNE, Australia, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Propanc Biopharma, Inc. ( NASDAQ:PPCB ) ( "Propanc" or the "Company" ) , a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a ...

Related tickers